Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era

Annals of Hematology

Volumn 92, Issue 4, 2013, Pages 471-479

  Yang, Deok Hwan ^a   Ahn, Jae Sook ^a   Byun, Byung Hyun ^a   Min, Jung Joon ^a   Kweon, Sun Seog ^a   Chae, Yee Soo ^b   Sohn, Sang Kyun ^b   Lee, Sang Woo ^b   Kim, Hae Won ^b   Jung, Sung Hoon ^a   Kim, Yeo Kyeoung ^a   Kim, Hyeoung Joon ^a   Bom, Hee Seung ^a   Lee, Je Jung ^a,c  

^a Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^b Kyungpook National University Hospital   (South Korea)

^c Chonnam National University   (South Korea)

Author keywords

Diffuse large B cell lymphoma; Interim PET CT; Prognosis; R CHOP chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; MONOCLONAL ANTIBODY; PREDNISONE; R CHOP PROTOCOL; R-CHOP PROTOCOL;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL PREDICTION; TREATMENT OUTCOME; TUMOR VOLUME; DECISION SUPPORT SYSTEM; DISEASE COURSE; EVALUATION; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SCINTISCANNING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PREDNISONE; PROGNOSIS; VINCRISTINE; YOUNG ADULT;

MLCS; MLOWN;

EID: 84877045694     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1640-x     Document Type: Article

References (32)

1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242
2. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126
3. 18F]fluoro-2-deoxy- d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106:1376-1381
4. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR (2005) FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16:1514-1523
5. Querellou S, Valette F, Bodet-Milin C, Oudoux A, Carlier T, Harousseau JL, Chatal JF, Couturier O (2006) FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol 85:759-767
6. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16:1160-1168
7. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D'Amore F, Boesen AM, Berthelsen AK, Specht L (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59
8. Yoo C, Lee DH, Kim JE, Jo J, Yoon DH, Sohn BS, Kim SW, Lee JS, Suh C (2011) Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol 90:797-802
9. Terasawa T, Lau J, Bardet S, Couturier O, Hotta T, Hutchings M, Nihashi T, Nagai H (2009) Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 27:1906-1914
10. Mikhaeel NG (2009) Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now. Leuk Lymphoma 50:1931-1936
11. Huttmann A, Muller S, Jockel KH, Duhrsen U (2010) Pitfalls of interim positron emission tomography scanning in diffuse large B-cell lymphoma. J Clin Oncol 28:e488-e489, author reply e490-1
12. Meignan M, Gallamini A, Haioun C (2009) Report on the first international workshop on interim-pet-scan in lymphoma. Leuk Lymphoma 50:1257-1260
13. 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background. J Nucl Med 51:1857-1862
14. Michallet AS, Trotman J, Tychyj-Pinel C (2010) Role of early PET in the management of diffuse large B-cell lymphoma. Curr Opin Oncol 22:414-418
15. 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 37:494-504
16. Zhu D, Ma T, Niu Z, Zheng J, Han A, Zhao S, Yu J (2011) Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer 73:332-337
17. Wu X, Dastidar P, Pertovaara H, Korkola P, Jarvenpaa R, Rossi M, Koobi T, Eskola H, Kellokumpu-Lehtinen PL (2011) Early treatment response evaluation in patients with diffuse large B-cell lymphoma - a pilot study comparing volumetric MRI and PET/CT. Mol Imaging Biol 13:785-792
18. Yang DH, Min JJ, Song HC, Jeong YY, Chung WK, Bae SY, Ahn JS, Kim YK, Bom HS, Chung IJ, Kim HJ, Lee JJ (2011) Prognostic significance of interim (1)(8)F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Eur J Cancer 47:1312-1318
19. Meignan M, Gallamini A, Haioun C, Polliack A (2010) Report on the second international workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma 51:2171-2180
20. Rijbroek A, Boellaard R, Vriens EM, Lammertsma AA, Rauwerda JA (2009) Comparison of transcranial Doppler ultrasonography and positron emission tomography using a three-dimensional template of the middle cerebral artery. Neurol Res 31:52-59
21. Hong R, Halama J, Bova D, Sethi A, Emami B (2007) Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning. Int J Radiat Oncol Biol Phys 67:720-726
22. 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. Nucl Med Commun 26:689-694
23. Moskowitz CH, Schoder H, Teruya-Feldstein J et al (2010) Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 28:1896-1903
24. Han HS, Escalon MP, Hsiao B, Serafini A, Lossos IS (2009) High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol 20:309-318
25. 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 50:527-533
26. 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 48:1626-1632
27. Juweid ME, Smith B, Itti E, Meignan M (2010) Can the interim fluorodeoxyglucose-positron emission tomography standardized uptake value be used to determine the need for residual mass biopsy after dose-dense immunochemotherapy for advanced diffuse large B-cell lymphoma. J Clin Oncol 28:e719-e720, author reply e721-712
28. Spaepen K, Stroobants S, Dupont P, Bormans G, Balzarini J, Verhoef G, Mortelmans L, Vandenberghe P, De Wolf-Peeters C (2003) [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction. Eur J Nucl Med Mol Imaging 30:682-688
29. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med 52:386-392
30. Cheson BD (2011) Role of functional imaging in the management of lymphoma. J Clin Oncol 29:1844-1854
31. Casasnovas RO, Meignan M, Berriolo-Riedinger A, Bardet S, Julian A, Thieblemont C, Vera P, Bologna S, Briere J, Jais JP, Haioun C, Coiffier B, Morschhauser F (2011) SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 118:37-43
32. Horning SJ, Juweid ME, Schoder H et al (2010) Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood 115:775-777, quiz 918